FDA Advises Against Antifungal Drug's Use In Studies

Law360, New York (October 16, 2013, 3:42 PM EDT) -- The U.S. Food and Drug Administration advised drugmakers on Wednesday not to use Johnson & Johnson's antifungal treatment Nizoral or similar oral medications in drug interaction studies, saying the risk of liver and kidney injury is too great.

The recommendation comes nearly three months after the FDA unveiled extensive warnings about the treatment, which is known generically as ketoconazole. The agency said in July that even short-term use of the medication's oral form can lead to serious liver and kidney damage.

Ketoconazole belongs to a class...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.